Antibody Engineering & Antibody Therapeutics 2011

Updated: June 30, 2011

Bronze Sponsor

Lonza is a leading partner to the pharmaceutical, healthcare and life science industries. For over a quarter century Lonza has been helping companies of all sizes improve and advance their products process development services and cGMP manufacturing of fine chemicals, (advanced) intermediates, (highly) active pharmaceutical ingredients, conjugates, peptides, recombinant proteins, monoclonal antibodies, research products, and cell-based therapeutics.

Technology Workshop Sponsors
	Antitope is a privately-held biotechnology research company focused on the development of non-immunogenic protein therapeutics. The company offers services for the assessment and removal of immunogenicity and the engineering of therapeutic proteins. To date, Antitope has entered into over 100 different agreements with pharmaceutical and biotechnology companies worldwide to apply its technologies for the development of improved biologics.
	Founded in 2002, based in Stockholm, Sweden, Attana AB develops biosensors for the pharmaceutical, diagnostic and academic society worldwide. With a strong focus on characterizing molecular interactions exactly as they occur in the human body, Attana is committed to increasing success during clinical trials by providing the life science community with biologically relevant information. Attana's biosensors can be used to determine specificity, kinetics and affinity, amongst other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.
	For over 50 years, Bio-Rad Laboratories has provided instrumentation and reagents supporting life science research. In 2006 Bio-Rad launched the ProteOn™ XPR36 protein interaction array system, which offers a novel 6 x 6 criss-cross fluidics design and unique referencing options to measure 36 simultaneous kinetic interactions in real time. With the ProteOn XPR36 system you can continue to rely on Bio-Rad for tools, technologies, and expertise that enable genomic and proteomic analysis.
	Dyax is an integrated biopharmaceutical company built on proprietary phage display technology. This technology discovered Dyax's lead product, ecallantide, approved under the brand name KALBITOR® in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Dyax leverages this technology broadly as part of its Licensing and Funded Research Program (LFRP). The success of the Company's LFRP royalty portfolio is illustrated by the program's advanced licensee pipeline that includes 17 candidates in clinical development. Of them, four candidates are in Phase 3 clinical trials, four are in Phase 2 and nine are in Phase 1.
	ForteBio markets a novel, label-free, 96 or 384-well format detection platform that includes instrument hardware, biosensors and data analysis software to measure affinity, kinetics, and concentration in crude or purified samples. This real-time dip and read method allows greater throughput and cost-effectiveness in many applications compared to existing methods such as SPR, ELISA and HPLC.
	MESO SCALE DISCOVERY® (MSD) markets kits and services for singleplex and multiplex biomarker assays. The assays are suitable for studies with pre-clinical and clinical samples for biomarkers of toxicology, neurodegeneration, signal transduction, inflammation, and metabolic disease among others. All assays exhibit exceptional sensitivity, wide dynamic range and a convenient workflow.
	MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying its technologies, MorphoSys has become a leader in the field of therapeutic antibodies.
	NovImmune SA is a drug discovery and development company with a focus on therapeutic mAbs for inflammatory diseases and immune-related disorders. NovImmune has generated, to date, seven proprietary mAbs. Three compounds are at this time in clinical development, with the most advanced in Phase II. Moreover, NovImmune also created a proprietary platform for the generation of fully human mono-, pan- and bispecific antibodies.
	Open Monoclonal Technology, Inc. ("OMT") is a private, California-based biotechnology company that has developed a fully human monoclonal antibody (mAb) platform based on transgenic rats. This new technology is the result of breakthroughs in the understanding of B-cell development and a novel approach to the inactivation of endogenous antibody expression. OMT's antibody platform has broad freedom to operate and uses technology protected by a new patent application. For more information, visit www.omtinc.net.
	X-BODY BioSciences generates and optimizes hMABs under mammalian folding conditions by dsDNA display of fully human libraries. Deep sequencing of thousands of hits provides an early read on the function, affinity and specificity of lead candidates. HuMaturation™ and proprietary VL pairing methodology allows for optimization of binding properties while maintaining their fully human character.

Badge & Lanyard Sponsor
	Micromet, Inc. (Nasdaq: MITI) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer.

Event Guide Co-Sponsor

nameplate

目录下载(PDF)

Event Information

CSS

Cutting-Edge Basic Science Combined with Updates on Clinical Progress

赞助商

footer